Intercept Pharmaceuticals’ attempt at creating a next-generation FXR agonist for certain forms of liver inflammation appears to have ended. The drug developer’s INT-787 showed “no

The most candid man in pharma strikes again. When asked on Tuesday’s earnings call whether Pfizer would consider a “transformative M&A” deal in the near

BioNTech is making big cuts to its manufacturing footprint. The German company said in its first-quarter earnings release that up to 1,860 manufacturing staff could

When I first heard about Parsley Health close to a decade ago, the startup embodied a few trends I was following closely: primary care startups

A blood test might predict who will respond to Wegovy; Viridian’s thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬